The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate-Reference-Cited by-同舟云学术

The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate

Published:2023-05-25 Issue:9 Volume:51 Page:1216-1226
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Udomnilobol Udomsak^ORCID,Jianmongkol Suree^ORCID,Prueksaritanont Thomayant

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference24 articles.

1. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans

2. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions--an Industry Perspective

3. Phase 0/microdosing approaches: time for mainstream application in drug development?;Burt;Nat Rev Drug Discov,2020

4. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin

5. EMA (2012) European Medicines Agency. Guideline on the investigation of drug interactions. Committee for Human Medicinal Products, CHMP.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies;Pharmaceutics;2024-07-26

2. Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model;Frontiers in Pharmacology;2024-03-07

3. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents;Clinical Pharmacokinetics;2023-09-20